Advanced Search


Smoking accelerates lung function decline1

Smoking/Lung function decline graph

Mean annual decline in FEV1 in 208 never-smokers, 697 ex-smokers, and 22 current smokers with severe Alpha-11

  • In a registry study of 927 patients with Alpha-1, 78.7% of patients were either current smokers (8.1%) or ex-smokers (70.6%)1

Oxidant-mediated stress damages lungs5

Smoking/Oxidative stress on lungs

Cigarette smoke2,3:

  • Contains oxidants capable of inactivating AAT2
  • Recruits inflammatory cells and increases neutrophil elastase concentration5

Passive smoking can be detrimental to lung function2,4

Help carriers of Alpha-1 learn how to quit smoking. Get information from the American Lung Association.

Help carriers stay healthy. Download Managing Environmental Risk Factors, a brochure from AlphaNet that you can share with your patients.

next: For Your Alpha Carriers >

Important Safety Information

PROLASTIN-C, Alpha1-Proteinase Inhibitor (Human) is indicated for chronic augmentation and maintenance therapy in adults with emphysema due to deficiency of alpha1-proteinase inhibitor (alpha1-antitrypsin deficiency). The effect of augmentation therapy with any alpha1-proteinase inhibitor (alpha1-PI) on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials. PROLASTIN-C is not indicated as therapy for lung disease in patients in whom severe Alpha1-PI deficiency has not been established.

PROLASTIN-C may contain trace amounts of IgA. Patients with known antibodies to IgA, which can be present in patients with selective or severe IgA deficiency, have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions. PROLASTIN-C is contraindicated in patients with antibodies against IgA.

The most common drug related adverse reactions during clinical trials in ≥ 1% of subjects were chills, malaise, headache, rash, hot flush, and pruritus.

PROLASTIN-C is made from human plasma. Products made from human plasma may carry a risk of transmitting infectious agents, e.g., viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Please see accompanying PROLASTIN-C Full Prescribing Information for complete prescribing details.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

References
  1. Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med. 1998;158(1):49-59.
  2. American Thoracic Society/European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818-900.
  3. DeMeo DL, et al. Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency. Thorax. 2007;62(9):806-813.
  4. Mayer AS, Stoller JK, Vedal S, et al. Risk factors for symptom onset in PI*Z alpha-1 antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis. 2007;1(4):485-492.
  5. MacNee W. Chest. 2000;117(5 suppl 1):303S-317S. Copyright 2000 by American College of Chest Physicians. Reproduced with permission of American College of Chest Physicians via Copyright Clearance Center.